[go: up one dir, main page]

WO2005037246A3 - Wässrige aerosol-zubereitung - Google Patents

Wässrige aerosol-zubereitung Download PDF

Info

Publication number
WO2005037246A3
WO2005037246A3 PCT/EP2004/011571 EP2004011571W WO2005037246A3 WO 2005037246 A3 WO2005037246 A3 WO 2005037246A3 EP 2004011571 W EP2004011571 W EP 2004011571W WO 2005037246 A3 WO2005037246 A3 WO 2005037246A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparations
administering
aqueous aerosol
active substances
aerosol preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/011571
Other languages
English (en)
French (fr)
Other versions
WO2005037246A2 (de
Inventor
Juergen Jauernig
Frank-Christophe Lintz
Manfred Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PARI GmbH
Original Assignee
PARI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PARI GmbH filed Critical PARI GmbH
Priority to EP04790427A priority Critical patent/EP1673066A2/de
Priority to AU2004281531A priority patent/AU2004281531A1/en
Priority to MXPA06004132A priority patent/MXPA06004132A/es
Priority to NZ546824A priority patent/NZ546824A/en
Priority to CA002542666A priority patent/CA2542666A1/en
Priority to BRPI0415470-3A priority patent/BRPI0415470A/pt
Priority to US11/106,999 priority patent/US7758886B2/en
Publication of WO2005037246A2 publication Critical patent/WO2005037246A2/de
Publication of WO2005037246A3 publication Critical patent/WO2005037246A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es werden sterile wässrige Zubereitungen für die Inhalation als Aerosol beschrieben, die einen Wirkstoff, ein nichtionisches Tensid und ein Phospholipid enthalten. Die Zubereitungen eignen sich zur inhalativen Verabreichung von schwerlöslichen Wirkstoffen in Form von kolloidalen Lösungen. Sie können ferner zur Verabreichung von schlecht schmeckenden, die Schleimhaut reizenden, Husten oder Bronchokonstriktionen auslösenden Wirkstoffen eingesetzt werden. Die Zubereitungen lassen sich mit gängigen Geräten vernebeln und mit Vorteil in der Pädiatrie einsetzen.
PCT/EP2004/011571 2003-10-15 2004-10-14 Wässrige aerosol-zubereitung Ceased WO2005037246A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP04790427A EP1673066A2 (de) 2003-10-15 2004-10-14 Wässrige aerosol-zubereitung
AU2004281531A AU2004281531A1 (en) 2003-10-15 2004-10-14 Aqueous aerosol preparation
MXPA06004132A MXPA06004132A (es) 2003-10-15 2004-10-14 Preparacion acuosa en aerosol.
NZ546824A NZ546824A (en) 2003-10-15 2004-10-14 Aqueous aerosol preparation
CA002542666A CA2542666A1 (en) 2003-10-15 2004-10-14 Aqueous aerosol preparation
BRPI0415470-3A BRPI0415470A (pt) 2003-10-15 2004-10-14 preparação em aerossol aquosa
US11/106,999 US7758886B2 (en) 2003-10-15 2005-04-14 Pharmaceutical aerosol composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10347994.5 2003-10-15
DE10347994A DE10347994A1 (de) 2003-10-15 2003-10-15 Wässrige Aerosol-Zubereitung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/106,999 Continuation-In-Part US7758886B2 (en) 2003-10-15 2005-04-14 Pharmaceutical aerosol composition

Publications (2)

Publication Number Publication Date
WO2005037246A2 WO2005037246A2 (de) 2005-04-28
WO2005037246A3 true WO2005037246A3 (de) 2005-12-08

Family

ID=34441978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011571 Ceased WO2005037246A2 (de) 2003-10-15 2004-10-14 Wässrige aerosol-zubereitung

Country Status (10)

Country Link
US (1) US7758886B2 (de)
EP (1) EP1673066A2 (de)
AU (1) AU2004281531A1 (de)
BR (1) BRPI0415470A (de)
CA (1) CA2542666A1 (de)
DE (1) DE10347994A1 (de)
MX (1) MXPA06004132A (de)
NZ (1) NZ546824A (de)
RU (1) RU2363449C2 (de)
WO (1) WO2005037246A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2001076671A2 (en) 2000-04-11 2001-10-18 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
US6904908B2 (en) 2002-05-21 2005-06-14 Trudell Medical International Visual indicator for an aerosol medication delivery apparatus and system
CA2526362C (en) 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1712220A1 (de) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmazeutische Aerosolzusammensetzung
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
US9205050B2 (en) 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
EP1820493A3 (de) * 2006-02-10 2008-05-07 PARI Pharma GmbH Aerosole für die Arzneistoffabgabe in den Nasennebenhöhlen
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en) 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
MX2008014418A (es) * 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
MX2009004198A (es) * 2006-10-17 2009-10-19 Lithera Inc Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
KR100868295B1 (ko) 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
CA3201293A1 (en) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
EP3398611B1 (de) * 2007-04-18 2020-08-12 Particle Sciences, Inc. Aerosoldispersionen von partikeln mit wirkstoffen
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US20090053149A1 (en) * 2007-08-24 2009-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
EP2030644A1 (de) * 2007-08-31 2009-03-04 PARI Pharma GmbH Nasensprays zur sinunasalen Arzneimittelfreisetzung
CA2698683A1 (en) * 2007-09-07 2009-03-12 Epigenesis Pharmaceuticals, Llc Dheas inhalation compositions
US20100305080A1 (en) * 2007-10-25 2010-12-02 O'shea Paul Novel Crystalline Salts of Montelukast
RU2369397C2 (ru) * 2007-12-10 2009-10-10 Виталий Георгиевич Пшеничников Назальное лекарственное средство "мореназал"
EP2237788A4 (de) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
EP2242526A4 (de) * 2008-02-15 2014-06-18 Timothy Sean Immel Aerosol-therapievorrichtung mit hochfrequenz-abgabe
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
CA2727432C (en) 2008-06-12 2016-10-11 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
WO2009156706A1 (en) * 2008-06-27 2009-12-30 University Of Strathclyde Pulmonary drug delivery with vesicles comprising non-ionic surfactants
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2477030A (en) * 2010-01-15 2011-07-20 Lithera Inc Lyophilised forms of fluticasone, salmeterol and combinations thereof
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
DK2366408T3 (da) * 2010-03-01 2012-10-22 Salvat Lab Sa Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
RU2419417C1 (ru) * 2010-03-31 2011-05-27 Виталий Георгиевич Пшеничников Фармацевтическая композиция в виде раствора флуконазола, обладающая противогрибковым действием
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
EP2593056B1 (de) 2010-07-15 2020-10-21 Eyenovia, Inc. Vorrichtung zur tropfenerzeugung
CA2805425C (en) 2010-07-15 2019-07-23 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
FR2971713B1 (fr) * 2011-02-18 2019-03-29 Laboratoire De La Mer Solution ionique aqueuse contenant de l'eau de mer et au moins un compose originellement non miscible a l'eau de mer.
US20120237550A1 (en) * 2011-03-16 2012-09-20 Siemens Healthcare Diagnostics Inc. Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
CN102872017B (zh) * 2011-07-13 2015-02-04 中国科学院上海药物研究所 6-(4-(二氟甲氧基)-3-甲氧基苯基)哒嗪-3(2h)-酮在制备抗肿瘤药物中的用途
US20130150812A1 (en) 2011-12-12 2013-06-13 Corinthian Ophthalmic, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
MX369828B (es) 2012-05-21 2019-11-22 Insmed Inc Sistemas para tratar infecciones pulmonares.
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP2886121A1 (de) * 2013-12-23 2015-06-24 Dr. Falk Pharma Gmbh Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
US10286163B1 (en) * 2014-03-04 2019-05-14 Philip J. Paustian On demand aerosolized delivery inhaler
EP3466432B1 (de) 2014-05-15 2020-07-08 Insmed Incorporated Verfahren zur behandlung von pulmonaler mykobakterieller nichttuberkuloseinfektionen
KR101669556B1 (ko) * 2014-07-02 2016-10-28 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
CA2945604C (en) * 2014-08-08 2022-08-23 Shenzhen Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
CN106137981B (zh) * 2015-04-15 2019-10-15 中国医学科学院医药生物技术研究所 一种达比加群酯冻干纳米混悬剂及其制备方法
EP3331522A1 (de) 2015-08-07 2018-06-13 Patara Pharma LLC Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017199215A1 (en) 2016-05-19 2017-11-23 Trudell Medical International Smart valved holding chamber
EP3481476B1 (de) 2016-07-08 2021-09-08 Trudell Medical International Intelligente schwingende vorrichtung für positiven exspiratorischen druck
US10786638B2 (en) 2016-07-08 2020-09-29 Trudell Medical International Nebulizer apparatus and method
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
JP7093353B2 (ja) 2016-12-09 2022-06-29 トゥルーデル メディカル インターナショナル スマートネブライザ
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
RU2684563C2 (ru) * 2017-08-14 2019-04-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ терапевтического лечения медикаментозного ринита, сформировавшегося на фоне приема назальных деконгестантов
US12114688B2 (en) * 2017-10-24 2024-10-15 Rai Strategic Holdings, Inc. Method for formulating aerosol precursor for aerosol delivery device
CA3086890A1 (en) 2018-01-04 2019-07-11 Trudell Medical International Smart oscillating positive expiratory pressure device
WO2019173884A1 (pt) * 2018-03-15 2019-09-19 Bebeachibuli Romeo Normalizador biológico, processo de obtenção de normalizador biológico e produtos obtidos com o normalizador biológico
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN108619118A (zh) * 2018-04-16 2018-10-09 郭丽颖 一种肺部吸入用布地奈德自组装胶束
CN112292158A (zh) * 2018-05-19 2021-01-29 加里·本雅明 泡沫制剂和向身体递送的方法
CN112384199A (zh) 2018-06-04 2021-02-19 阿尔库缇斯股份有限公司 改善罗氟司特皮肤渗透滞后时间的方法和制剂
CN112368009A (zh) 2018-06-27 2021-02-12 呼吸治疗公司 包含大环免疫抑制剂的可吸入的组合物
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
EA202092892A1 (ru) * 2018-12-04 2021-05-27 Брес Терапьютикс Гмбх Ингаляционные композиции, содержащие макроциклические иммуносупрессанты
AU2020338979B2 (en) 2019-08-27 2025-09-25 Trudell Medical International Inc. Smart oscillating positive expiratory pressure device
RU2730938C1 (ru) * 2019-11-05 2020-08-26 Василий Михайлович Ахунов Способ профилактики бронхиальной астмы при инфекции грибом рода Peacilomyces
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
KR20230020952A (ko) 2020-04-01 2023-02-13 유니온 테라퓨틱스 에이/에스 치료
MX2022012359A (es) 2020-04-01 2022-10-21 Union Therapeutics As Formulacion.
US20230355898A1 (en) * 2020-09-22 2023-11-09 Micronization Technologies And Therapeutics Group Llc Nebulizer and nebulized anti-virals
AU2021393513A1 (en) 2020-12-04 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5470583A (en) * 1992-12-11 1995-11-28 Eastman Kodak Company Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
WO1997042938A1 (en) * 1996-05-14 1997-11-20 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU76682A1 (de) 1977-02-01 1977-06-27
US4150071A (en) 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
DE4203306A1 (de) 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
DE4322111C2 (de) 1993-07-02 2001-05-10 Pari Gmbh Inhalationsvernebler
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
IT1277832B1 (it) 1995-03-02 1997-11-12 Giuseppina Magni Confezione per sostanze nebulizzabili
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69804832T2 (de) * 1997-10-08 2002-11-07 Sepracor Inc., Marlborough Dosierungsform zur verabreichung von aerosolen
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000027376A2 (de) 1998-10-26 2000-05-18 Michael Schedler Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
GB0009612D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10145361A1 (de) 2001-09-14 2003-04-03 Pari Gmbh Verfahren zur Herstellung von flüssigen, sterilen Zubereitungen zur Inhalation
EP1438019A1 (de) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Set für die herstellung einer pharmazeutischen zusammensetzung
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
EP2319585A1 (de) 2002-08-29 2011-05-11 Cipla Ltd. Pharmazeutische Produkte und Zusammensetzungen enthaltend Salmeterol, Fluticason und Ipratropium oder Tiotropium
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5470583A (en) * 1992-12-11 1995-11-28 Eastman Kodak Company Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
WO1997042938A1 (en) * 1996-05-14 1997-11-20 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19

Also Published As

Publication number Publication date
WO2005037246A2 (de) 2005-04-28
DE10347994A1 (de) 2005-06-16
RU2363449C2 (ru) 2009-08-10
BRPI0415470A (pt) 2006-12-19
CA2542666A1 (en) 2005-04-28
NZ546824A (en) 2010-01-29
US7758886B2 (en) 2010-07-20
EP1673066A2 (de) 2006-06-28
AU2004281531A1 (en) 2005-04-28
RU2006114451A (ru) 2007-11-20
MXPA06004132A (es) 2006-06-27
US20050244339A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005037246A3 (de) Wässrige aerosol-zubereitung
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2006108556A3 (en) Pharmaceutical aerosol composition
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2004071439A3 (en) Immunoglobulin formulation and method of preparation thereof
WO2002017881A3 (en) Transdermal pharmaceutical delivery composition
SE0102276D0 (sv) Device and method for the administration of a medicament
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
CY1109223T1 (el) Υγρα σκευασματα toy g-csf
TW200517142A (en) Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability
ATE415943T1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
WO2007090822A3 (de) Pharmazeutische formulierung für aerosole mit zwei oder mehr wirkstoffen und mindestens einer oberflächenaktiven substanz
AU2003294879A1 (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
MY137752A (en) Medicament for treating aseptic inflammations containing anemonin as effective component
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
MXPA04005783A (es) Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
EP0682942A4 (de) Neue, perkutan absorbierbare zubereitung.
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
WO2005048985A3 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2005037256A3 (de) Flüssige zubereitung enthaltend tobramycin
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2005027976A3 (en) Composition comprising ether lipid
WO2003030862A3 (en) Anaesthetic compositions and method for their administration

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11106999

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004790427

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004132

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2542666

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004281531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1075/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 546824

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006114451

Country of ref document: RU

Ref document number: A20060450

Country of ref document: BY

ENP Entry into the national phase

Ref document number: 2004281531

Country of ref document: AU

Date of ref document: 20041014

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004281531

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004790427

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415470

Country of ref document: BR